255735-88-7

Basic information

• Product Name: Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI);(2-Aminopropyl)carbamic acid tert-butyl ester;CarbaMic acid, (2-aMinopropyl)-, 1,1-diMethylethyl ester;CarbaMic acid, N-(2-aMinopropyl)-, 1,1-diMethylethyl ester
• CAS NO: 255735-88-7
• Molecular Formula: C₈H₁₈N₂O₂
• Molecular Weight: 174.24072
• Product Categories: N-BOC
• Mol File: 255735-88-7.mol

Chemical Properties

• Boiling Point: 263.719 °C at 760 mmHg
• Flash Point: 113.293 °C
• Appearance: /
• Density: 0.984g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.454
• Storage Temp.: 2-8°C(protect from light)
• Solubility: DCM, Hexane, Ethyl Acetate
• PKA: 12.51±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI)(255735-88-7)
• EPA Substance Registry System: Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI)(255735-88-7)

Safety Data

• Hazardous Substances Data: 255735-88-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of Misoprostol (M368755), a cytoprotective prostaglandin PGE analogue. Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI) plays a crucial role in the development of medications that can help protect the gastrointestinal tract and reduce the risk of ulcers and other gastrointestinal complications.
As an intermediate in the synthesis of Misoprostol, Carbamic acid, (2-aminopropyl)-, 1,1-dimethylethyl ester (9CI) contributes to the development of a drug that has various applications, including the prevention of gastric ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs), the treatment of gastric ulcers, and the induction of labor in pregnant women. Its role in the synthesis process highlights its importance in the pharmaceutical industry and its potential impact on human health.

InChI:InChI=1/C8H18N2O2/c1-6(9)5-10-7(11)12-8(2,3)4/h6H,5,9H2,1-4H3,(H,10,11)

Upstream product

• 13303-10-1 tert-Butyl 4-nitrophenyl carbonate 
• 78-90-0 1,2-diaminopropan 
• 6627-89-0 tert-butyl phenyl carbonate 
• 149602-64-2 1-azido-2-(N-tert-butoxycarbonylamino)propane 
• 110-89-4 piperidine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 851017-82-8 3-[(2-benzyloxycarbonyl-ethyl)-(2-tert-butoxycarbonylamino-1-methyl-ethyl)-amino]-propionic acid benzyl ester 
• 851017-84-0 3-[(2-benzyloxycarbonyl-ethyl)-(2-{3-[(2-{2-[bis-(2-benzyloxycarbonyl-ethyl)-amino]-propylcarbamoyl}-ethyl)-(2-tert-butoxycarbonylamino-1-methyl-ethyl)-amino]-propionylamino}-1-methyl-ethyl)-amino]-propionic acid benzyl ester 
• 1059191-59-1 tert-Butyl (2-{[7-(2,4-dichlorophenyl)imidazo[1,2-c]pyrimidin-5-yl]amino}propyl)carbamate 
• 1003577-91-0 tert-butyl (2-{[(4-ethoxyphenyl)carbonyl]amino}-propyl)carbamate 
• 1003577-93-2 tert-butyl [2-({[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl}amino)propyl]carbamate 

Relevant articles and documents

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS

The invention relates to 1,2-diamido-ethylene derivatives of the formula (I) wherein R1, R2, R3, and A are as described in the description and their use as medicaments, especially as orexin receptor antagonists.

PIPERAZINYL ANTIVIRAL AGENTS

Provided are compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

FATTY ACID ACETYLATED SALICYLATES AND THEIR USES

The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.

1,2-DIAMIDO-ETHYLENE DERIVATIVES

The invention relates to 1,2-diamido-ethylene derivatives of the formula (I) NHNR 3 OAOR 1 R 2 (I) wherein R1, R 2, R 3, and A are as described in the description and their use as medicaments, especially as orexin receptor

Hydrogen bond catalyzed chemoselective N-tert-butoxycarbonylation of amines

A novel, chemoselective mono-N-Boc protection of various structurally diverse amines with di-tert-butoxypyrocarbonate (Boc)2O is described that relies on selective carbonyl activation by hydrogen bond formation. This mild, acid- and metal-free process requires only catalytic amounts of thiourea as hydrogen bond donor.

1,1,1,3,3,3-Hexafluoroisopropanol: A recyclable organocatalyst for N-Boc protection of amines

A simple and efficient protocol for the chemoselective mono-N-Boc protection of various structurally diverse amines with di-tert-butyl dicarbonate using 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) as solvent and catalyst is described. The catalyst can be readily separated from the reaction products and recovered for direct reuse. No competitive side reactions such as formation of isocyanate, urea, and N,N-di-Boc were observed. α-Amino alcohols afforded the N-Boc derivatives without oxazolidinone formation. Georg Thieme Verlag Stuttgart.

Convergent synthesis of internally branched PAMAM dendrimers

(Chemical Equation Presented) A series of aliphatic internally branched poly(amido amine) dendrons and dendrimers has been synthesized. The internal branching unit was 1,2-propanediamine and a series of PAMAM-type dendrons of the types AB2, AB4, and AB8 were built. These were anchored on a core molecule containing four carboxylic acid moieties and the 1,2-propanediamine unit resulted in PAMAM dendrimers with 4, 8, 16, and 32 end groups.

NOVEL ETHYLENEDIAMINE DERIVATIVES

A compound represented by the following formula (1):Q-Q-T-N(R)-Q-N(R)-T-Q [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: -C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4-C(R3f)(R4f)- (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents -COCONR- or the like]; or salt thereof, solvate thereof, or N-oxide thereof. The compound is useful as a preventive and/or therapeutic agent for cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.